UY39768A - Anticuerpo agonista de pd–1 humano y composición farmacéutica que comprende el anticuerpo para trata - Google Patents
Anticuerpo agonista de pd–1 humano y composición farmacéutica que comprende el anticuerpo para trataInfo
- Publication number
- UY39768A UY39768A UY0001039768A UY39768A UY39768A UY 39768 A UY39768 A UY 39768A UY 0001039768 A UY0001039768 A UY 0001039768A UY 39768 A UY39768 A UY 39768A UY 39768 A UY39768 A UY 39768A
- Authority
- UY
- Uruguay
- Prior art keywords
- antibody
- human
- agonist
- trafficking
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021081913 | 2021-05-13 | ||
| JP2021086534 | 2021-05-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY39768A true UY39768A (es) | 2022-11-30 |
Family
ID=84029692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001039768A UY39768A (es) | 2021-05-13 | 2022-05-13 | Anticuerpo agonista de pd–1 humano y composición farmacéutica que comprende el anticuerpo para trata |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240317859A1 (https=) |
| EP (1) | EP4339289A4 (https=) |
| JP (1) | JPWO2022239820A1 (https=) |
| KR (1) | KR20240007203A (https=) |
| AR (1) | AR125887A1 (https=) |
| AU (1) | AU2022272835A1 (https=) |
| BR (1) | BR112023023400A2 (https=) |
| CA (1) | CA3217199A1 (https=) |
| IL (1) | IL307887A (https=) |
| MX (1) | MX2023013207A (https=) |
| TW (1) | TW202311290A (https=) |
| UY (1) | UY39768A (https=) |
| WO (1) | WO2022239820A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230183347A1 (en) * | 2020-05-25 | 2023-06-15 | Foundation For Biomedical Research And Innovation At Kobe | PD-1 Agonist-Containing Pharmaceutical Composition for Treating or PReventing TH2-Mediated Disease |
| KR20250122541A (ko) | 2022-10-25 | 2025-08-13 | 사이즈믹 테라퓨틱, 인코포레이티드. | 변이체 IgG FC 폴리펩티드 및 그 용도 |
| CN117024595B (zh) * | 2023-10-08 | 2024-01-26 | 江西乐成欣生生物技术研究有限责任公司 | 抗人st2的单克隆抗体及其应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| AU2009290544B2 (en) * | 2008-09-12 | 2015-07-16 | Oxford University Innovation Limited | PD-1 specific antibodies and uses thereof |
| TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| ES2893855T3 (es) * | 2011-08-11 | 2022-02-10 | Ono Pharmaceutical Co | Agente terapéutico para enfermedades autoinmunes que comprende agonista de PD-1 |
| DK3237446T3 (en) * | 2014-12-22 | 2021-07-26 | Pd 1 Acquisition Group Llc | Anti-PD-1-antistoffer |
| BR112018006237A2 (pt) | 2015-09-29 | 2018-10-09 | Celgene Corp | proteínas de ligação a pd-1 e métodos de uso das mesmas |
| CR20190550A (es) | 2017-06-05 | 2020-04-05 | Janssen Biotech Inc | Anticuerpos que se unen específicamente a pd-1 y métodos de uso |
| TWI890481B (zh) | 2018-02-09 | 2025-07-11 | 日商小野藥品工業股份有限公司 | 雙特異性抗體 |
| AR114127A1 (es) * | 2018-03-02 | 2020-07-22 | Lilly Co Eli | Anticuerpos agonistas contra pd-1 y usos de estos |
| KR20210010896A (ko) | 2018-05-14 | 2021-01-28 | 이뮤노코어 리미티드 | 이기능성 결합 폴리펩타이드 |
| KR20250126805A (ko) | 2019-06-05 | 2025-08-25 | 아납티스바이오, 아이엔씨. | Pd-1 작용제 및 이의 사용 방법 |
| JP7185614B2 (ja) | 2019-11-18 | 2022-12-07 | 株式会社エクスモーション | 情報処理装置、及び情報処理プログラム |
| JP7310572B2 (ja) | 2019-11-29 | 2023-07-19 | 日本電気株式会社 | 計数装置、制御方法、及びプログラム |
| US20230183347A1 (en) * | 2020-05-25 | 2023-06-15 | Foundation For Biomedical Research And Innovation At Kobe | PD-1 Agonist-Containing Pharmaceutical Composition for Treating or PReventing TH2-Mediated Disease |
-
2022
- 2022-05-12 WO PCT/JP2022/020011 patent/WO2022239820A1/ja not_active Ceased
- 2022-05-12 JP JP2023521233A patent/JPWO2022239820A1/ja active Pending
- 2022-05-12 AU AU2022272835A patent/AU2022272835A1/en active Pending
- 2022-05-12 IL IL307887A patent/IL307887A/en unknown
- 2022-05-12 CA CA3217199A patent/CA3217199A1/en active Pending
- 2022-05-12 US US18/290,006 patent/US20240317859A1/en active Pending
- 2022-05-12 BR BR112023023400A patent/BR112023023400A2/pt unknown
- 2022-05-12 EP EP22807519.8A patent/EP4339289A4/en active Pending
- 2022-05-12 KR KR1020237042168A patent/KR20240007203A/ko active Pending
- 2022-05-12 MX MX2023013207A patent/MX2023013207A/es unknown
- 2022-05-13 AR ARP220101298A patent/AR125887A1/es unknown
- 2022-05-13 UY UY0001039768A patent/UY39768A/es unknown
- 2022-05-13 TW TW111118052A patent/TW202311290A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20240317859A1 (en) | 2024-09-26 |
| MX2023013207A (es) | 2023-11-15 |
| EP4339289A4 (en) | 2025-10-08 |
| IL307887A (en) | 2023-12-01 |
| AU2022272835A9 (en) | 2023-11-16 |
| AR125887A1 (es) | 2023-08-23 |
| AU2022272835A1 (en) | 2023-11-02 |
| KR20240007203A (ko) | 2024-01-16 |
| WO2022239820A1 (ja) | 2022-11-17 |
| CA3217199A1 (en) | 2022-11-17 |
| BR112023023400A2 (pt) | 2024-01-23 |
| EP4339289A1 (en) | 2024-03-20 |
| JPWO2022239820A1 (https=) | 2022-11-17 |
| TW202311290A (zh) | 2023-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY39768A (es) | Anticuerpo agonista de pd–1 humano y composición farmacéutica que comprende el anticuerpo para trata | |
| CL2021001630A1 (es) | Anticuerpos biespecíficos anti-cd28 x anti-cd22 y usos de estos | |
| CL2020003285A1 (es) | Anticuerpos anti-psma x anti-cd28 biespecificos y usos de estos. | |
| CL2024002093A1 (es) | Anticuerpos anti-cd73. | |
| EA202092410A1 (ru) | Конъюгаты камптотецина с пептидом | |
| MX2022009596A (es) | Anticuerpos anti-ror1 y composiciones. | |
| MX2023014643A (es) | Un grupo de anticuerpos monoclonales b7h3 y uso medico del mismo. | |
| BR112015010360A2 (pt) | anticorpo isolado ou fragmento de ligação a antígeno do mesmo que pode se ligar especificamente ao sítio ii de uma il-6 humana, seus usos, ácido nucleico, composição, vetor, célula, e processo para produzir a mesma | |
| DOP2011000004A (es) | Agentes y antagonistas fijadores de notch y metodos para el uso de los mismos | |
| NI202000051A (es) | Anticuerpos monoclonales y métodos para utilizar los mismos. | |
| CR20220058A (es) | Conjugados peptídicos de citotoxinas como terapéuticos | |
| PE20081635A1 (es) | Agentes para suprimir la reaccion de rechazo cronica | |
| MX386491B (es) | Metodos para reducir los niveles de suero de agentes que contienen fc que usan antagonistas de fcrn. | |
| BR112012004546A8 (pt) | Terapêutica por proteínas ligantes dll4-ligantes | |
| MX2021010453A (es) | Conjugados anticuerpo-farmaco que comprenden anticuerpos contra dlk1 humana y uso de estos. | |
| CO6541558A2 (es) | Anticuerpos neutralizantes anti-ngf humanos como inhibidores selectivos de la vía de ngf | |
| MX2022003668A (es) | Metodos y composiciones para el tratamiento de la retinopatia diabetica. | |
| CO2021009689A2 (es) | Anticuerpos monoclonales que se unen específicamente a la región beta de la familia trbv-9 del receptor de células t humano, y los métodos para su uso. | |
| EA201591191A1 (ru) | Антитела против ntb-a и связанные с ними композиции и способы | |
| EA202190059A1 (ru) | Конъюгаты связующее-активное средство, направленные против cxcr5, имеющие ферментативно расщепляемые линкеры и улучшенный профиль активности | |
| CO2021008204A2 (es) | Anticuerpos monoclonales que se unen específicamente a la región beta de la familia trbv-9 del receptor de células t humano, y los métodos para su uso | |
| CL2021001607A1 (es) | Anticuerpos anti-pmel17 y conjugados de los mismos | |
| BR112021020116A2 (pt) | Anticorpos anti-integrina e usos dos mesmos | |
| BR112022009482A2 (pt) | Anticorpo monoclonal anti-b7-h3 e métodos de uso do mesmo | |
| MX2024003107A (es) | Agonistas de ahr. |